Advanced Enzyme Technologies Balance Sheet Health
Financial Health criteria checks 6/6
Advanced Enzyme Technologies has a total shareholder equity of ₹13.9B and total debt of ₹256.9M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are ₹15.5B and ₹1.6B respectively. Advanced Enzyme Technologies's EBIT is ₹1.7B making its interest coverage ratio -16.8. It has cash and short-term investments of ₹5.1B.
Key information
1.8%
Debt to equity ratio
₹256.89m
Debt
| Interest coverage ratio | -16.8x |
| Cash | ₹5.07b |
| Equity | ₹13.89b |
| Total liabilities | ₹1.60b |
| Total assets | ₹15.49b |
Recent financial health updates
No updates
Recent updates
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Aug 20
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Jul 19Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Financial Position Analysis
Short Term Liabilities: ADVENZYMES's short term assets (₹8.1B) exceed its short term liabilities (₹1.0B).
Long Term Liabilities: ADVENZYMES's short term assets (₹8.1B) exceed its long term liabilities (₹564.4M).
Debt to Equity History and Analysis
Debt Level: ADVENZYMES has more cash than its total debt.
Reducing Debt: ADVENZYMES's debt to equity ratio has reduced from 2.5% to 1.8% over the past 5 years.
Debt Coverage: ADVENZYMES's debt is well covered by operating cash flow (553.6%).
Interest Coverage: ADVENZYMES earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:56 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Advanced Enzyme Technologies Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| null null | DBS Bank Ltd |
| Dhananjay Sinha | Emkay Global Financial Services Ltd. |